Literature DB >> 10748946

Cognitive, social, and economic costs of allergic rhinitis.

M S Blaiss1.   

Abstract

Allergic rhinitis is a highly prevalent, chronic condition. In addition to physical discomfort, rhinitis symptoms have been associated with detrimental effects on the psychological and social aspects of patients' lives. In allergy-specific questionnaires, subjects with allergic rhinitis consistently report lower quality of life than nonallergic controls. Untreated patients are embarrassed and frustrated by their allergy symptoms. Atopic individuals consistently exhibit significant declines in cognitive processing, psychomotor speed, verbal learning, and memory during allergy season. The discomfort, cognitive impairment, and absenteeism associated with allergic rhinitis exact a significant economic toll on U.S. businesses through decreased productivity. When combined with direct medical expenditures, the economic burden of allergic rhinitis is considerable. The effect of treatment on the economics of allergic rhinitis is highly variable: relatively inexpensive medications (lower direct costs) have central nervous system side effects that can cause somnolence and impair learning, memory, and performance (higher indirect costs). Health outcomes data on the effects of allergic rhinitis and its treatments can help establish, monitor, and improve standards of care; as well as inform priority setting, direct resource allocation, and eliminate unnecessary practices.

Entities:  

Mesh:

Year:  2000        PMID: 10748946     DOI: 10.2500/108854100778248953

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  15 in total

1.  Validation of the work and health interview.

Authors:  Walter F Stewart; Judith A Ricci; Carol Leotta; Elsbeth Chee
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 2.  The safety and efficacy of desloratadine for the management of allergic disease.

Authors:  William E Berger
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  The cost of treating allergic rhinitis.

Authors:  David A Stempel; Roger Woolf
Journal:  Curr Allergy Asthma Rep       Date:  2002-05       Impact factor: 4.806

Review 4.  Prevalence and differential diagnosis of chronic rhinitis.

Authors:  J W Georgitis
Journal:  Curr Allergy Asthma Rep       Date:  2001-05       Impact factor: 4.806

5.  Maternal stress and perinatal programming in the expression of atopy.

Authors:  Rosalind J Wright; Michelle Bosquet Enlow
Journal:  Expert Rev Clin Immunol       Date:  2008-09-01       Impact factor: 4.473

6.  Effect of sunlight exposure on cognitive function among depressed and non-depressed participants: a REGARDS cross-sectional study.

Authors:  Shia T Kent; Leslie A McClure; William L Crosson; Donna K Arnett; Virginia G Wadley; Nalini Sathiakumar
Journal:  Environ Health       Date:  2009-07-28       Impact factor: 5.984

7.  Health-care cost reduction resulting from primary-care allergy testing in children in Italy.

Authors:  Niklas Zethraeus; Carl Johan Petersson; Massimiliano Dozzi; Magnus P Borres; Giulio Vignati; Alessandro Fiocchi
Journal:  Ital J Pediatr       Date:  2010-09-13       Impact factor: 2.638

8.  Cost-effectiveness analysis of mometasone furoate versus beclomethasone dipropionate for the treatment of pediatric allergic rhinitis in Colombia.

Authors:  Carlos E Rodríguez-Martínez; Monica P Sossa-Briceño; Elkin Vladimir Lemos
Journal:  Adv Ther       Date:  2015-03-10       Impact factor: 3.845

9.  Effect of allergic rhinitis on the use and cost of health services by children with asthma.

Authors:  Hye-Young Kang; Choon Seon Park; Hye Ryun Bang; Vasilisa Sazonov; Chul Joon Kim
Journal:  Yonsei Med J       Date:  2008-08-30       Impact factor: 2.759

10.  Attitudes, practices on allergic rhinitis of three socioeconomic classes of Filipinos in the National Capital Region.

Authors:  Cecilia Gretchen Navarro-Locsin; Joel A Romualdez
Journal:  Asia Pac Allergy       Date:  2016-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.